Aytu BioPharma Third Quarter 2025 Earnings: Beats Expectations

Aytu BioPharma (NASDAQ:AYTU) Third Quarter 2025 Results

Key Financial Results

• Revenue: US$18.5m (up 2.6% from 3Q 2024).
• Net income: US$3.94m (up from US$2.89m loss in 3Q 2024).
• Profit margin: 21% (up from net loss in 3Q 2024).
• EPS: US$0.64 (up from US$0.52 loss in 3Q 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Aytu BioPharma Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 34%. Earnings per share (EPS) also surpassed analyst estimates.

Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 114% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Aytu BioPharma you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.